María Natalia Gandur Quiroga: After a successful ESMO 23, ADC continues to shine

María Natalia Gandur Quiroga shared a post on X/Twitter:

“After a successful ESMO 23, ADC continues to shine. A critical question for the future of ADC: Who will be their ideal partner?
ADCs are vital anticancer drugs for solid and hematological malignancies.

• Regulatory approvals obtained mainly as single agents, limited success in combinations.
• Ideal partners enhance effects without overlapping toxicities.
• Active forerunners: antiangiogenic compounds, HER2-targeting drugs, DNA-damage response agents, and immune checkpoint inhibitors (ICIs).
• Next-gen ADCs: tumor-specific targets, improved conjugation tech, novel linkers and payloads.
• Clinical trials: patient preselection crucial based on target expression, response relationship, and safety considerations.
• Trial designs: robust hypotheses for combinations, Phase 1 combinatorial evaluations, dose escalation with adaptive strategies.
• Challenges: nonspecific target expression, overlapping toxicities, lack of efficacy in distinct tumor clones, resistance mechanisms.
• Solutions: optimizing ADC properties, patient selection based on predictive biomarkers, preclinical and window-of-opportunity clinical testing for rational combinations.”

For more information click here.
Source: María Natalia Gandur Quiroga/Twitter.

Maria Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Instituto de Oncología Ángel H. Roffo in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies. Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors.  She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.